Skip to main content
. 2023 Mar 14;164(8):1801–1809. doi: 10.1097/j.pain.0000000000002878

Table 1.

Sample characteristics.

Characteristic Participants with OUD and fibromyalgia Others with pain and OUD All participants
Gender, n (%)
 Female 20 (52.6) 29 (36.7) 49 (41.9)
 Male 18 (47.4) 50 (63.3) 68 (58.1)
Race, n (%)
 Black 8 (21.1) 21 (26.6) 29 (24.8)
 White 28 (73.7) 57 (72.2) 85 (72.6)
 Any other race 2 (5.3) 1 (1.3) 3 (2.6)
Ethnicity, n (%)
 Hispanic 2 (5.3) 2 (2.5) 5 (3.8)
 Non-Hispanic 28 (73.7) 77 (97.5) 113 (96.6)
Opioid type, n (%)
 Fentanyl 27 (69.2) 69 (80.2) 96 (76.8)
 Heroin 12 (30.8) 31 (36.0) 43 (34.4)
 Prescription opioid 10 (25.6) 17 (19.8) 27 (21.6)
OUD severity, mean (SD)
 DSM-5 OUD criteria 10.5 (1.6) 10.6 (1.3) 10.6 (1.3)
Mental health, mean (SD)
 RAND-36 Mental Health domain score 37.6 (14.5) 49.3 (17.2) 45 (17.2)
Bodily pain, mean (SD)
 RAND-36 Bodily Pain domain score 31.7 (16.3) 54.5 (23.1) 47.3 (23.6)
Painful body regions, mean (SD)
 Body regions 6 (2.9) 2.4 (1.3) 3.7 (2.7)
Pain-related OUD Exacerbation Scale, mean (SD)
 PROUD ES score 12.1 (3.6) 9.5 (4.1) 10.3 (4.1)

Ten participants were missing demographics. Age was unintentionally omitted. Greater than 6 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria indicates severe opioid use disorder (OUD). Research and Development-36 (RAND-36) domains are scaled 0 to 100 with lower scores indicating worse health in that domain (ie, worse pain or mental health). Greater Pain-related OUD Exacerbation Scale scores indicate greater endorsement of pain-related OUD exacerbations.